PFizer’s (PFE) Promising New HIV Drug
August 6, 2007 by Douglas A. McIntyrePfizer (PFE) has FDA approval for a new drug that "blocks the CCR5 co-receptor that serves as a main doorway for the HIV virus into immune cells." It will be marketed as Selzentry and is the first of a new generation of drugs that will bring new pharma R&D to the fight against AIDs.
According to industry analysts, the drug could have annual sales of $500 million within three to four years.
A January research study described the new treatment "a potent new class of antiyirals for the treatment of HIV infection"
Given the PR beating the drug companies take, it is good to see some positive news.
Pfizer could use it. The company is trying to rebuild in the face of generic competition. In an interview with The Associated Press a company executive was upbeat about progress: "I think so far we’re on track to deliver on the goal of tripling the number of compounds in the Phase III pipeline by 2009," said John LaMattina, president of Pfizer’s global research and development.
The company’s shares closed at $24.11 today, within hailing distance of their 52-week low.
Douglas A. McIntyre
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.